| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.1 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | -0.44 | 0.1 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.047 | 0.1 |